Meanwhile, CD105 can more specifically mark tumor angiogenesis without reacting with the original normal vascular ECs; thus, it is expected to be a new target for anti-tumor angiogenesis therapy in the future and a more ideal vascular EC marker compared with CD31 and CD34. Here, PECAM1 is linked to neoplasm.